ONCOLYTICS BIOTECH INC
ONCY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ONCY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously administered immunotherapeutic agent, for the treatment of gastrointestinal cancers, with a lead program in second-line metastatic colorectal cancer.
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$109.2M
Cash Runway
1.8 moLead Asset
pelareorep (Phase 1/Phase 2)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 1 catalyst for ONCOLYTICS BIOTECH INC.
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously administered immunotherapeutic agent, for the treatment of gastrointestinal cancers, with a lead program in second-line metastatic colorectal cancer.
- Lead drug candidate is pelareorep, an intravenously administered immunotherapeutic agent being developed for gastrointestinal cancers [sec_mda · as of 2026-08-12].
- Cash and cash equivalents were $4.1 million as of June 30, 2026 [sec_mda · as of 2026-08-12].
- Net loss of $9.4 million for the quarter ended June 30, 2026 [latest reported financials (as of 2026-06-30)].
- The company has incurred operating losses since inception and expects to continue to incur losses for the foreseeable future [sec_mda · as of 2026-08-12].
- A going concern uncertainty exists; the company may need to reduce or delay activities if additional funding is not obtained [sec_mda · as of 2026-08-12].
What works
- Pelareorep is being evaluated in a randomized second-line metastatic colorectal cancer clinical study, with potential to advance to registration-enabled studies [sec_mda · as of 2026-08-12].
- The company is exploring multiple strategic partnership options and engaging with collaborators to advance development [sec_mda · as of 2026-08-12].
- Preclinical work is ongoing to evaluate pelareorep in combination with RAS pathway-targeting agents, expanding potential indications [sec_mda · as of 2026-08-12].
What to weigh
- The company has a going concern qualification and may need to reduce or delay research and development activities if additional funding is not obtained [sec_mda · as of 2026-08-12].
- Cash and cash equivalents of $4.1 million as of June 30, 2026, are limited relative to the costs of late-stage clinical trials and manufacturing [sec_mda · as of 2026-08-12].
- The company does not expect to generate significant revenues unless and until pelareorep receives regulatory approval and becomes commercially viable [sec_mda · as of 2026-08-12].
- Future capital requirements are uncertain and depend on clinical trial timing, regulatory outcomes, and partnership opportunities [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $4,115.”
SEC MD&A · August 12, 2026
Going concern uncertainty
“The accompanying condensed consolidated financial statements have been prepared on a going‑concern basis and do not include any adjustments that might result from the outcome of these uncertainties.”
SEC MD&A · August 12, 2026
Lead clinical program in second-line mCRC
“In 2026, our clinical objectives will primarily revolve around our randomized second-line mCRC clinical study.”
SEC MD&A · August 12, 2026
No significant revenues expected until regulatory approval
“We do not expect to generate significant revenues unless and until pelareorep receives regulatory approval and becomes commercially viable.”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · pelareorep — Phase 2 Readout: pelareorep — Topline data from the Phase 2 trial of pelareorep in second-line metastatic colorectal cancer is expected by the end of 2026.
Risks & what to watch (4)›
Key risks
- Going concern risk — The company may need to reduce or delay R&D activities if additional funding is not obtained [sec_mda · as of 2026-08-12].
- Limited cash runway — Cash of $4.1M as of June 30, 2026, is insufficient to fund late-stage trials without new financing [sec_mda · as of 2026-08-12].
- Regulatory and commercial uncertainty — No significant revenues expected unless pelareorep gains regulatory approval, which is uncertain [sec_mda · as of 2026-08-12].
- Dependence on partnerships — Future capital requirements depend on partnerships or collaborations, which may not materialize [sec_mda · as of 2026-08-12].
What to watch
- Topline data from the Phase 2 pelareorep trial expected by end of 2026 [upcoming catalysts (authoritative, structured, real dates)].
- Ability to secure additional financing or partnerships to extend cash runway beyond current $4.1M [sec_mda · as of 2026-08-12].
- Progress of the second-line mCRC clinical study and any regulatory interactions [sec_mda · as of 2026-08-12].
- Preclinical results from combination studies with RAS pathway inhibitors [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run ONCOLYTICS BIOTECH INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ONCOLYTICS BIOTECH INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
1.8 months
OCF -$8M · Net income -$9M
Lead: Phase 1/Phase 2
1 candidate
1 upcoming, next in ~123d
2 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$731K
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 859,831 | $731K |
| sound income strategies, llc | 194 | $180 |
Short Interest
as of Apr 20, 2026- % of float
- 5.4%
- Days to cover
- 8.1
- Shares short
- 6,184,650
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ONCY short interestGovernance
Frequently asked questions
What is the AI investment thesis for ONCOLYTICS BIOTECH INC?
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously administered immunotherapeutic agent, for the treatment of gastrointestinal cancers, with a lead program in second-line metastatic colorectal cancer.
What is ONCOLYTICS BIOTECH INC's lead drug candidate?
ONCOLYTICS BIOTECH INC's most advanced tracked candidate is pelareorep (Phase 1/Phase 2) for Ras-mutated Metastatic Colorectal Cancer; Anal Cancer Metastatic.
What is ONCOLYTICS BIOTECH INC's next catalyst?
ONCOLYTICS BIOTECH INC's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: pelareorep" — expected December 31, 2026.
Who is the CEO of ONCOLYTICS BIOTECH INC?
Mr. Jared Kelly J.D., L.L.M. is the chief executive officer of ONCOLYTICS BIOTECH INC (ONCY).
Where is ONCOLYTICS BIOTECH INC headquartered?
ONCOLYTICS BIOTECH INC (ONCY) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.